TCRX TScan Therapeutics Inc

Price (delayed)

$6.89

Market cap

$364.22M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.18

Enterprise value

$310.44M

Highlights
The EPS has soared by 61% YoY and by 13% QoQ
The equity has soared by 58% YoY but it has contracted by 18% from the previous quarter
The company's net income fell by 33% YoY and by 8% QoQ
TScan Therapeutics's revenue has decreased by 30% QoQ and by 14% YoY

Key stats

What are the main financial stats of TCRX
Market
Shares outstanding
52.86M
Market cap
$364.22M
Enterprise value
$310.44M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.68
Price to sales (P/S)
44.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.96
Earnings
Revenue
$14.81M
EBIT
-$93.04M
EBITDA
-$87.92M
Free cash flow
-$70.05M
Per share
EPS
-$1.18
Free cash flow per share
-$0.74
Book value per share
$2.57
Revenue per share
$0.16
TBVPS
$2.54
Balance sheet
Total assets
$240.83M
Total liabilities
$117.87M
Debt
$91.76M
Equity
$122.97M
Working capital
$133.24M
Liquidity
Debt to equity
0.75
Current ratio
5.23
Quick ratio
5.33
Net debt/EBITDA
0.61
Margins
EBITDA margin
-593.6%
Gross margin
100%
Net margin
-653.5%
Operating margin
-689.2%
Efficiency
Return on assets
-34.5%
Return on equity
-61.1%
Return on invested capital
-53.7%
Return on capital employed
-44.4%
Return on sales
-628.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TCRX stock price

How has the TScan Therapeutics stock price performed over time
Intraday
-0.43%
1 week
-2.96%
1 month
6%
1 year
208.97%
YTD
18.18%
QTD
17.78%

Financial performance

How have TScan Therapeutics's revenue and profit performed over time
Revenue
$14.81M
Gross profit
$14.81M
Operating income
-$102.09M
Net income
-$96.8M
Gross margin
100%
Net margin
-653.5%
The operating margin has plunged by 63% YoY and by 55% from the previous quarter
TScan Therapeutics's net margin has shrunk by 56% YoY and by 54% QoQ
The company's operating income fell by 39% YoY and by 9% QoQ
The company's net income fell by 33% YoY and by 8% QoQ

Growth

What is TScan Therapeutics's growth rate over time

Valuation

What is TScan Therapeutics stock price valuation
P/E
N/A
P/B
2.68
P/S
44.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.96
The EPS has soared by 61% YoY and by 13% QoQ
The price to book (P/B) is 79% higher than the last 4 quarters average of 1.5
The equity has soared by 58% YoY but it has contracted by 18% from the previous quarter
The price to sales (P/S) is 95% higher than the last 4 quarters average of 22.6
TScan Therapeutics's revenue has decreased by 30% QoQ and by 14% YoY

Efficiency

How efficient is TScan Therapeutics business performance
The ROS has shrunk by 55% QoQ and by 54% YoY
TScan Therapeutics's ROIC has increased by 36% YoY but it has decreased by 7% from the previous quarter
The company's return on assets rose by 18% YoY
TScan Therapeutics's ROE has increased by 10% YoY

Dividends

What is TCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TCRX.

Financial health

How did TScan Therapeutics financials performed over time
The total assets is 104% greater than the total liabilities
The total assets has increased by 39% year-on-year but it has declined by 12% since the previous quarter
TCRX's current ratio is down by 27% year-on-year and by 20% since the previous quarter
TScan Therapeutics's debt is 25% lower than its equity
The equity has soared by 58% YoY but it has contracted by 18% from the previous quarter
The debt to equity has declined by 31% year-on-year but it has increased by 23% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.